陈国安副教授、博士生导师


cheng@sustech.edu.cn
生物楼505
进入个人主页返回到师资列表
个人简介陈国安，南科大医学院副教授，博导。1986年毕业于西安交通大学医学院医疗系，1992年获西安交通大学医学院呼吸专业硕士学位。1999年获协和医科大学肿瘤学博士学位。1986至1996年其间就职于西安交通大学医学院第二附属医院呼吸内科，先后任住院医师和主治医师。2000年至2018年在美国密歇根大学(University of Michigan)医学院先从事肿瘤学博士后研究，以后历任讲师，研究助理教授和研究副教授。主要研究方向是肿瘤分子生物学，功能基因组学及生物信息学。应用高通量技术如蛋白质谱，基因表达芯片，单核苷酸突变（SNP）芯片，miRNA芯片以及核苷酸二代测序等研究肺癌组织及血中蛋白，RNA 及DNA的变化。近年来以非编码RNA，包括miRNAs, lncRNA和circRNA，为重点探讨其在肿瘤发生发展中的作用及分子机理以及其在临床诊断，预后判断和治疗中的价值。作为项目主持人或主要成员承担过省,国家自然科学基金和美国国家或其他基金研究项目10余项。拥有3项转化医学有关的专利，是20余SCI杂志的审稿专家， 3个杂志的编委。发表研究论文100余篇，其中SCI论文80余篇，影响因子（IF）大于9的有37篇，如Nature Medicine, Nature Biotechnology, Cancer Cell, JNCI，J Clinical Investigation, Nature Communications, Cancer Research, Clinical Cancer Research, J Thoracic Oncology，Genome Research， Developmental Cell, PNAS等国际知名杂志，总影响因子超过660。作为第一作者或通讯作者有47篇，作为第一作者的单篇论文最高总引超过980次，论文总引超过8800次，h-index 41, i10-index 64(Google scholar)。
研究领域肺癌分子生物学
肺癌功能基因组学
肺癌非编码RNA
肺癌转移和耐药的机制研究



教育背景2000.03-2003.01，肿瘤学博士后研究，美国密歇根大学医学院
1996.9-1999.6，肿瘤学博士，中国协和医科大学/中国医学科学院
1988.09-1992.06，呼吸专业硕士，西安交通大学
1981.09-6/1986.06，临床医学学士，西安交通大学



工作经历2018.10 - 至今 副教授，南方科技大学医学院
2017.09 - 2018.10研究副教授，美国密歇根大学医学院
2010.09 - 2017.08研究助理教授，密歇根大学医学院
2004.11 - 2010.08 讲师，密歇根大学医学院
2003.02 - 2004.10 Research Associate，密歇根大学医学院
1986.07 - 1996.08住院医师/主治医师，西安交通大学大学第二附属医院



近年代表文章Balbin OA, Malik R, Dhanasekaran SM, Prensner JR, Cao X, Wu YM, Robinson D, Wang R, Chen G, Beer DG, Nesvizhskii AI, Chinnaiyan AM. The landscape of antisense gene expression in human cancers. Genome Res. 2015 Jul;25(7):1068-79. PMID:** (IF:10.101).
He Y, Wang L, Liu W, Zhong J, Bai S, Wang Z, Thomas DG, Lin J, Reddy RM, Ramnath N, Carrott PW, Lynch WR, Orringer MB, Chang AC, Beer DG, Chen G*. MAP3K3 expression in tumor cells and tumor-infiltrating lymphocytes is correlated with favorable patient survival in lung cancer. Sci Rep. 2015 Jun 19;5:11471. PMID: ** (*通讯作者) (IF:4.122).
Goswami MT*, Chen G*, Chakravarthi BV, Pathi SS, Anand SK, Carskadon SL, Giordano TJ, Chinnaiyan AM, Thomas DG, Palanisamy N, Beer DG, Varambally S. Role and regulation of coordinately expressed de novo purine biosynthetic enzymes PPAT and PAICS in lung cancer. Oncotarget. 2015 Sep 15; 6(27):23445-61. PMID: ** (* co-first authors) (IF:5.168).
Nadal E, Truini A, Nakata A, Lin J, Reddy RM, Chang AC, Ramnath N, Gotoh N, Beer DG, Chen G*. A Novel Serum 4-microRNA Signature for Lung Cancer Detection. Sci Rep. 2015 Jul 23; 5:12464. PMID: ** (*通讯作者) (IF:4.122).
Zhao L, Feng D, Chen G, Taylor JM. A unified Bayesian semiparametric approach to assess discrimination ability in survival analysis. Biometrics. 2015 Dec 17. PMID: ** (IF:1.524).
Wang L, He Y, Liu W, Bai S, Xiao L, Zhang J, Dhanasekaran SM, Wang Z, Kalyana-Sundaram S, Balbin OA, Shukla S, Lu Y, Lin J, Reddy RM, Carrott PW Jr, Lynch WR, Chang AC, Chinnaiyan AM, Beer DG, Zhang J, Chen G*. Non-coding RNA LINC00857 is predictive of poor patient survival and promotes tumor progression via cell cycle regulation in lung cancer. Oncotarget. 2016 Feb 5. PMID: ** (*通讯作者) (IF:5.168).
Raghunathan R, Cease K, Troeschel S, Zhao L, Gross M, Chen G, Chopra V, Ramnath N. Impact of Staging with Positron-emission Tomography (PET) and Comorbidities on Management and Survival of American Veterans with Stage I-III Non-Small Cell Lung Cancer. Am J Clin Oncol. 2016 Jun 17. PMID:** (IF:3.424).
Shukla S, Evans JR, Malik R, Feng FY, Dhanasekaran SM, Cao X, Chen G, Beer DG, Jiang H, Chinnaiyan AM. Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma. J Natl Cancer Inst. 2016 Oct 5;109(1). doi: 10.1093/jnci/djw200. Print 2017 Jan.PMID:** (IF:12.589).
Shiratsuchi H, Wang Z, Chen G, Ray P, Lin J, Zhang Z, Zhao L, Beer D, Ray D, Ramnath N. Oncogenic Potential of CYP24A1 in Lung Adenocarcinoma. J Thorac Oncol. 2017 Feb;12(2):269-280. doi: 10.1016/j.jtho.2016.10.010. Epub 2016 Oct 26. PMID:** (IF:12.460).
Xu J, Zhou W, Yang F, Chen G, Li H, Zhao Y, Liu P, Li H, Tan M, Xiong X, Sun Y. The β-TrCP-FBXW2-SKP2 axis regulates lung cancer cell growth with FBXW2 acting as a tumour suppressor. Nat Commun. 2017 Jan 16;8:14002. PMID: ** (IF:12.353).
Zhang J, Feng S, Su W, Bai S, Xiao L, Wang L, Thomas DG, Lin J, Reddy RM, Carrott PW, Lynch WR, Chang AC, Beer DG, Guo YM, Chen G*. Overexpression of FAM83H-AS1 indicates poor patient survival and knockdown impairs cell proliferation and invasion via MET/EGFR signaling in lung cancer. Sci Rep. 2017 Feb 15;7:42819. PMID: ** (*通讯作者) (IF:4.122).
Liu Y, Bu L, Li W, Wu W, Wang S, Diao X, Zhou J, Chen G, Yang S. Increased AAA-TOB3 correlates with lymph node metastasis and advanced stage of lung adenocarcinoma. Int J Biol Markers. 2017 Jun 15: PMID:** (IF:1.449).
Feng S, Zhang J, Su W, Bai S, Xiao L, Chen X, Lin J, Reddy RM, Chang AC, Beer DG, Chen G*. Overexpression of LINC00152 correlates with poor patient survival and knockdown impairs cell proliferation in lung cancer. Sci Rep. 2017 Jun 7;7(1):2982. PMID: ** (*通讯作者) (IF:4.122).
Chockley PJ, Chen J, Chen G, Beer DG, Standiford TJ, Keshamouni VG. Epithelial-mesenchymal transition leads to NK cell-mediated metastasis-specific immunosurveillance in lung cancer. J Clin Invest. 2018 Jan 11. PMID: ** (IF:13.251).
Su W, Feng S, Chen X, Yang X, Mao R, Guo C, Wang Z, Thomas DG, Lin J, Reddy RM, Orringer MB, Chang AC, Yang Z, Beer DG, Chen G*. Silencing of long non-coding RNA MIR22HG triggers cell survival/death signaling via oncogenes YBX1, MET, and p21 in lung cancer. Cancer Res. 2018 Apr 18. PMID: ** (*通讯作者) (IF:9.130).
Guo NL, Dowlati A, Raese RA, Dong C, Chen G, Beer DG, Shaffer J, Singh S, Bokhary U, Liu L, Howington J, Hensing T, Qian Y. A Predictive 7-Gene Assay and Prognostic Protein Biomarkers for Non-small Cell Lung Cancer. EBioMedicine. 2018 May 31. PMID: ** (IF:6.680).
Raghunathan R, Cease K, Troeschel S, Zhao L, Gross M, Chen G, Chopra V, Ramnath N Impact of Staging With Positron-emission Tomography (PET) and Comorbidities on Managementand Survival of American Veterans With Stage I-III Non-Small Cell Lung Cancer. Am J Clin Oncol. 2018 May;41(5):513-518, PMID:** (IF:3.424).
Heiden BT, Chen G, Hermann M, Brown RKJ, Orringer MB, Lin J, Chang AC, Carrott PW, Lynch WR, Zhao L, Beer DG, Reddy RM. 18F-FDG PET intensity correlates with a hypoxic gene signature and other oncogenic abnormalities in operable non-small cell lung cancer. PloS One. 2018 Jul 2;13(7): PMID: ** (IF:2.766).
Yu H, Chen Z, Ballman KV, Watson MA, Govindan R, Lanc I, Beer DG, Bueno R, Chirieac LR, Chui MH, Chen G, Franklin WA, Gandara DR, Genova C, Brovsky KA, Joshi MM, Merrick DT, Richards WG, Rivard CJ, Harpole DH, Tsao MS, van Bokhoven A, Shepherd FA, Hirsch FR. Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signature for Prognosis in Early-Stage Squamous Cell Lung Carcinoma. J Thorac Oncol. 2019 Jan;14(1):25-36. PMID: ** (IF:12.460).
Su W, Wang L, Niu F, Zou L, Guo C, Wang Z, Yang X, Wu J, Lu Y, Zhang J, Beer DG, Yang Z, Chen G*. LINC00857 knockdown inhibits cell proliferation and induces apoptosis via involving STAT3 and MET oncogenic proteins in esophageal adenocarcinoma. Aging (Albany NY). 2019 May 13;11(9):2812-2821. PMID: ** (*通讯作者) (IF:5.515).
Cheng G, Zhang Q, Pan J, Lee Y, Ouari O, Hardy M, Zielonka M, Myers CR, Zielonka J, Weh K, Chang AC, Chen G, Kresty L, Kalyanaraman B, You M. Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis. Nat Commun. 2019 May 17;10(1):2205. PMID: ** (IF:11.878).
Li L, Kang J, Zhang W, Cai L, Wang S, Liang Y, Jiang Y, Liu X, Zhang Y, Ruan H, Chen G, Wang M, Jia L.Validation of NEDD8-conjugating enzyme UBC12 as a new therapeutic target in lung cancer. EBioMedicine. 2019 Jun 14. PMID: **(IF:6.680)
Yang X, Zhang Q, Zhang M, Su W, Wang Z, Li Y, Zhang J, Beer DG, Yang S, Chen G*. Serum microRNA Signature Is Capable of Early Diagnosis for Non-Small Cell Lung Cancer. Int J Biol Sci. 2019 Jun 10;15(8):1712-1722. doi: 10.7150/ijbs.33986. eCollection 2019. PMID: ** (*通讯作者) (IF:4.06)
Chen X, Mao R, Su W, Yang X, Geng Q, Guo C, Wang Z, Wang J, Kresty LA, Beer DG, Chang AC, Chen G*. Circular RNA circHIPK3 modulates autophagy via MIR124-3p-STAT3-PRKAA/AMPKα signaling in STK11 mutant lung cancer. Autophagy. 2019 Jun 23. doi: 10.1080/**.2019.**. [Epub ahead of print] PMID: ** (*通讯作者) (IF:11.059)
Su W, Guo C, Wang L, Wang Z, Yang X, Niu F, Tzou D, Yang X, Huang X, Wu J, Chen X, Zou L, Yang Z, Chen G. LncRNA MIR22HG abrogation inhibits proliferation and induces apoptosis in esophageal adenocarcinoma cells via activation of the STAT3/c-Myc/FAK signaling. Aging (Albany NY). 2019 Jul 10;11. doi: 10.18632/aging.102071. [Epub ahead of print] PMID: ** (*通讯作者) (IF: 5.515).
Yin Y, Xie CM, Li H, Tan M,Chen G, Schiff R, Xiong X, Sun Y.The FBXW2-MSX2-SOX2 axis regulates stem cell property and drug resistance of cancer cells.Proc Natl Acad Sci U S A. 2019 Sep 23. pii: . doi: 10.1073/pnas.. [Epub ahead of print] PMID: ** (IF:9.58)
Xia Yang, Wenmei Su, Xiuyuan Chen, Qianqian Geng, Jingyi Zhai, Hu Shan, Chunfang Guo, Zhuwen Wang, Han Fu, Hui Jiang, Jules Lin, Kiran Hari Lagisetty, Jie Zhang, Yali Li, Shuanying Yang, Pierre P Massion, David G. Beer, Andrew C. Chang, Nithya Ramnath,Guoan Chen*. Validation of A serum 4-microRNA signature for the detection of lung cancer.Translational Lung Cancer Research. 2019 Online (*通讯作者) (IF: 4.81).
Xia Yang, Qiuhong Zhang, Wenmei Su, Ming Zhang, Hu Shan, Jie Zhang,Guoan Chen, Chunfang Guo, Yali Li. Expression level of serum miRNA-22 and its clinical significance in patients with lung cancer.International Journal of Respiration.2019 Sep, 39(18), 1373-1378
Jiang Y, Cheng W, Li L, Zhou L, Liang Y, Zhang W, Chen W, Wang S, Zhao H, Chen G, Zhou W, Ji G, Zhang Y, Hoffman RM, Wang M, Jia L. Effective targeting of the ubiquitin-like modifier NEDD8 for lung adenocarcinoma treatment. Cell Biol Toxicol. 2020 Jan 6. doi: 10.1007/s10565-019-09503-6. [Epub ahead of print] PMID: ** (IF: 5.1).
Lyu X, Zeng L, Zhang H, Ke Y, Liu X, Zhao N, Yuan J, Chen G, Yang S. Hydroxychloroquine suppresses lung tumorigenesis via inducing FoxO3a nuclear translocation through STAT3 inactivation. Life Sci. 2020 Jan 27:117366. doi: 10.1016/j.lfs.2020.117366. [Epub ahead of print], PMID: ** (IF: 3.5).
Huang W, Ray P, Ji W, Wang Z, Nancarrow D, Chen G, Galban S, Lawrence TS, Beer DG, Rehemtulla A, Ramnath N, Ray D. The cytochrome P450 enzyme CYP24A1 increases proliferation of mutant KRAS-dependent lung adenocarcinoma independently of its catalytic activity. J Biol Chem. 2020 Mar 12. pii: jbc.RA119.011869. doi: 10.1074/jbc.RA119.011869. [Epub ahead of print] PMID: ** (IF: 4.13).